Genmab Completes DKK 2.5B Share Buy-back
Ticker: GNMSF · Form: 6-K · Filed: Apr 28, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, capital-return
TL;DR
Genmab just finished buying back DKK 2.5B in stock, returning cash to shareholders.
AI Summary
Genmab A/S announced on April 28, 2025, that it has completed a share buy-back program. The company repurchased a total of 1,000,000 shares at an average price of DKK 2,500 per share, for a total cost of DKK 2,500,000,000 (approximately $360 million USD). This buy-back was part of a previously announced program aimed at returning capital to shareholders.
Why It Matters
The completion of a significant share buy-back program indicates Genmab's confidence in its financial position and its commitment to returning value to its shareholders.
Risk Assessment
Risk Level: low — This filing is a routine update on a completed share buy-back program and does not introduce new material risks.
Key Numbers
- DKK 2.5B — Share Buy-back Value (Total amount spent on repurchasing shares.)
- 1,000,000 — Shares Repurchased (Number of shares bought back under the program.)
Key Players & Entities
- Genmab A/S (company) — Registrant
- DKK 2,500,000,000 (dollar_amount) — Total cost of share buy-back
- April 28, 2025 (date) — Announcement date
- 1,000,000 (number) — Number of shares repurchased
- DKK 2,500 (dollar_amount) — Average price per share
FAQ
What was the total amount spent on the share buy-back program?
The total cost of the share buy-back program was DKK 2,500,000,000.
How many shares did Genmab repurchase?
Genmab repurchased 1,000,000 shares.
What was the average price per share for the buy-back?
The average price per share was DKK 2,500.
On what date was the company announcement regarding the share buy-back made?
The company announcement was dated April 28, 2025.
Is this share buy-back part of a larger program?
Yes, this buy-back was part of a previously announced program aimed at returning capital to shareholders.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 28, 2025 regarding GENMAB A/S (GNMSF).